DNA microarray analysis of cannabinoid signaling in mouse brain in vivo.
To identify novel genes involved in cannabinoid receptor-mediated signaling, we used cDNA microarrays to detect changes in mRNA expression in the forebrains of mice 12 h after they were given a single intraperitoneal dose of the naturally-occurring Cannabis sativa alkaloid Delta(9)-tetrahydrocannabinol (Delta(9)-THC) or the synthetic cannabinoid receptor agonist (R)-(+)-2,3-dihydro-5-methyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3-de]-1,4-benzoxazin-yl-1-naphtalenylmethanone mesylate [R(+)-WIN 55,212-2]. Of approximately 11,000 genes from a mouse brain cDNA library that were probed, 65 showed altered (increased or decreased at least 2-fold) expression after exposure to Delta(9)-THC, 41 after exposure to R(+)-WIN 55,212-2, and 20 genes after exposure to both drugs. Genes affected similarly by Delta(9)-THC and R(+)-WIN 55,212-2 were considered likely to reflect cannabinoid receptor activation, and expression of the protein products of two such genes not previously implicated in cannabinoid signaling-melanocyte-specific gene-related gene 1 (MRG1) and hexokinase 4 (glucokinase, GK)-was measured by Western blotting and immunohistochemistry. Western blots showed approximately 2-fold increases in the levels of both proteins in mouse forebrain. Immunohistochemistry revealed preferential localization of MRG1 to cerebral blood vessels and of GK to hypothalamic neurons. These findings suggest that MRG1 and GK are cannabinoid-regulated genes and that they may be involved in the vascular and hypothalamic effects of cannabinoids, respectively.
Parmentier-Batteur
Sophie
S
Buck Institute for Age Research, Novato, California 94945, USA. dgreenberg@buckinstitute.org
Jin
Kunlin
K
Xie
Lin
L
Mao
Xiao Ou
XO
Greenberg
David A
DA
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D048588:Benzoxazines; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D002186:Cannabinoids / Q000378:metabolism*; D004268:DNA-Binding Proteins; D013759:Dronabinol / Q000494:pharmacology; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D005941:Glucokinase / Q000235:genetics*; D006213:Hallucinogens / Q000494:pharmacology; D008297:Male; D051379:Mice; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D020411:Oligonucleotide Array Sequence Analysis; D012097:Repressor Proteins; D015398:Signal Transduction / Q000502:physiology*; D015534:Trans-Activators / Q000235:genetics*
D000700:Analgesics; D048588:Benzoxazines; D002186:Cannabinoids; C110087:Cited2 protein, mouse; D004268:DNA-Binding Proteins; D006213:Hallucinogens; D009025:Morpholines; D009281:Naphthalenes; D012097:Repressor Proteins; D015534:Trans-Activators; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol; D005941:Glucokinase